Compounds for targeted degradation of Bruton's tyrosine kinase
EA202690720A1Pending Publication Date: 2026-10-30BIOGEN MA INC +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- EA202690720
- Authority / Receiving Office
- EA · EA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-05-05
- Filing Date
- 2022-05-05
- Publication Date
- 2026-10-30
Smart Images

Figure CLAIM-30102026-IMGA0001
Abstract
The present invention relates to compounds of formula (A): BTK-L-DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to a linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by formula (I) or formula (II) that is covalently attached to a linker L: where all variables are defined in the invention. The compounds or pharmaceutically acceptable salts thereof described herein are capable of activating the selective ubiquitination of Btk proteins via the ubiquitin-proteasome pathway (UPP) and causing the degradation of Btk proteins. The present invention also relates to methods for treating disorders responsive to the modulation of Btk activity and / or Btk degradation using at least one compound described herein.
Need to check novelty before this filing date? Find Prior Art
